Rhythm management in atrial fibrillation - With a primary emphasis on pharmacologic therapy: part 3

被引:14
作者
Kassotis, J
Costeas, C
Blitzer, M
Reiffel, JA
机构
[1] Columbia Univ, Dept Med, Div Cardiol, New York, NY USA
[2] Columbia Presbyterian Med Ctr, Electrophysiol & Pacemaker Lab, New York, NY USA
来源
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY | 1998年 / 21卷 / 05期
关键词
atrial fibrillation; antiarrhythmic drugs; cardioversion; rate control;
D O I
10.1111/j.1540-8159.1998.tb00160.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is the most common, sustained, symptomatic tachyarrhythmia that clinicians are called upon to manage. Management strategies include ventricular rate control coupled with anticoagulation, versus restoration and maintenance of sinus rhythm. Rate control may be achieved pharmacologically with agents that impair AV nodal conduction directly and/or by increasing parasympathetic/sympathetic balance, or by modifying or ablating the AV nodal region anatomically. Rhythm control may be achieved by electrical or pharmacologic conversion followed by maintenance of sinus rhythm by pharmacologic (or occasionally ablative) therapies. This article will present current approaches to rate and rhythm control issues in atrial fibrillation. Parts 1 and 2, published previously, dealt with rate control and with the restoration of sinus rhythm. Part 3, the current article, details the selection process of choosing a therapy to maintain sinus rhythm, including the likelihood of success, the risks of therapy, and individualization of therapy as dependent upon the nature of the structural heart disease present. It also discusses nonpharmacologic approaches that have been recently developed or are undergoing development. One suggested drug selection algorithm is provided.
引用
收藏
页码:1133 / 1145
页数:13
相关论文
共 64 条
[1]  
Aliot E, 1996, AM J CARDIOL, V77, pA66
[2]   CANADA CHEMICAL-INDUSTRY STRUGGLES TO RECOVER FROM RECESSION [J].
ANDERSON, E .
CHEMICAL & ENGINEERING NEWS, 1992, 70 (26) :11-12
[3]   PREVENTION OF SYMPTOMATIC RECURRENCES OF PAROXYSMAL ATRIAL-FIBRILLATION IN PATIENTS INITIALLY TOLERATING ANTIARRHYTHMIC THERAPY - A MULTICENTER, DOUBLE-BLIND, CROSSOVER STUDY OF FLECAINIDE AND PLACEBO WITH TRANSTELEPHONIC MONITORING [J].
ANDERSON, JL ;
GILBERT, EM ;
ALPERT, BL ;
HENTHORN, RW ;
WALDO, AL ;
BHANDARI, AK ;
HAWKINSON, RW ;
PRITCHETT, ELC .
CIRCULATION, 1989, 80 (06) :1557-1570
[4]   FLECAINIDE ACETATE FAR PAROXYSMAL SUPRAVENTRICULAR TACHYARRHYTHMIAS [J].
ANDERSON, JL ;
PLATT, ML ;
GUARNIERI, T ;
FOX, TL ;
MASER, MJ ;
PRITCHETT, ELC ;
KAY, GN ;
PLUMB, VJ ;
EPSTEIN, AE ;
BUBIEN, RS ;
BHANDARI, AK ;
LEON, C ;
BRINKLEY, AM ;
ROSIN, BL ;
MCCABE, E ;
DATORRE, S ;
DEBORDE, R ;
HAFFAJEE, C ;
RUFINO, K ;
DEGON, C ;
WEBB, CR ;
BIELINSKI, KA ;
DUNBAR, D ;
HEDGES, M ;
FJELDOOSPERBECK, K ;
GOMES, JA ;
WINTERS, S ;
PE, E ;
FOSTER, JR ;
WOELFEL, A ;
CULLINANE, L ;
MCCARTHY, EA ;
CHRISTIE, LG ;
CARLSON, KL ;
ALPERT, BL ;
FECIK, CM ;
MORENO, F ;
JOHNSON, L ;
SUMMERS, K ;
ELLENBOGEN, KA ;
MARTIN, ML ;
HART, WL ;
FRIEDMAN, NJ ;
NEUMANN, S ;
LAIDLAW, JC ;
STOLLINGS, L ;
CULLEN, MT ;
DONAHUE, PA ;
HAHN, MA ;
HAWKINSON, RW .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 74 (06) :578-584
[5]  
[Anonymous], 1989, NEW ENGL J MED, V321, P406
[6]   LONG-TERM ORAL PROPAFENONE THERAPY FOR SUPPRESSION OF REFRACTORY SYMPTOMATIC ATRIAL-FIBRILLATION AND ATRIAL-FLUTTER [J].
ANTMAN, EM ;
BEAMER, AD ;
CANTILLON, C ;
MCGOWAN, N ;
GOLDMAN, L ;
FRIEDMAN, PL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 12 (04) :1005-1011
[7]  
Bellandi F, 1996, G Ital Cardiol, V26, P379
[8]  
Boissel J P, 1981, Eur Heart J, V2, P49
[9]   Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT [J].
Cairns, JA ;
Connolly, SJ ;
Roberts, R ;
Gent, M .
LANCET, 1997, 349 (9053) :675-682
[10]  
CHICAMBARAM M, 1992, THORAC CARDIOVASC SU, V40, P70